Search

To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments. Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome. Of the 326 patients analyzed, 120 were cases confirmed by real-time PCR, 34 by a serologic test, and 205 were suspected. Sixty-nine patients (21.3%) developed severe infection, 10 (3%) critical, and 7 (2.1%) died. Ambulatory patients were higher in relapsing MS forms, treated with injectables and oral first-line agents, whereas more severe cases were observed in patients on pulsed immunosuppressors and critical cases among patients with no therapy. Severe and critical infections were more likely to affect older males with comorbidities, with progressive MS forms, a longer disease course, and higher disability. Fifteen of 33 patients treated with rituximab were hospitalized. Four deceased patients have progressive MS, 5 were not receiving MS therapy, and 2 were treated (natalizumab and rituximab). Multivariate analysis showed age (OR 1.09, 95% CI, 1.04-1.17) as the only independent risk factor for a fatal outcome. This study has not demonstrated the presumed critical role of MS therapy in the course of COVID-19 but evidenced that people with MS with advanced age and disease, in progressive course, and those who are more disabled have a higher probability of severe and even fatal disease

Diseño Estudio descriptivo, observacional, transversal y retrospectivo en el que revisamos las historias clínicas de los pacientes que acuden al módulo de enfermedades desmielinizantes del Servicio de NRL desde 17/7/79 hasta 5/3/19. Objetivos Describir la prevalencia de otras alteraciones autoinmunes en el momento del diagnóstico de la esclerosis múltiple. Métodos Revisamos historias clínicas con sistema SAP, se analizaron datos de pacientes diagnosticados de esclerosis múltiple desde 17/7/79 hasta 5/3/19 (577 historias). Seleccionamos, aquellas que dispusieran del estudio analítico inmunológico en el momento de diagnóstico (371 historias). Se rellenó una base de datos anonimizada con datos biográficos, referentes a la esclerosis múltiple, datos de RM, confirmación diagnóstica de EM, punción lumbar, analitica con marcadores inmunológicos (TSH, T4 libre, ANA, ANCA, Autoanticuerpo (Ac.) AntiTG, Ac. AntiTPO, Ac. Anti-ds DNA, Ac. Anti-Cardiolipina IgG, Ac. Anti-Cardiolipina IgM, Ac. Anti- β2 Glicoproteína I IgG, Ac. Anti- β2 Glicoproteína I IgM, Ac. Anti- Péptido de Gliadina IgA, Ac. Anti- Péptido de Gliadina IgG, Ac. Anti-Transglutaminasa tisular IgA, Ac. Anti-Transglutaminasa tisular IgG, Ac. Anti-Endomisio, Ac. Anti-MPO y Ac. Anti-PR3. Los datos extraídos fueron analizados empleando el IBM SPSS® Statistics realizando los cálculos pertinentes. Utilizamos descriptivos como media y desviaciones estándar y se agruparon variables con resultados expresados en porcentajes. Resultados Se aprecia un mayor número de mujeres en la muestra del estudio, representando una mayor afectación frente al sexo masculino. En cuanto a la clínica la mayoría de los pacientes se encontraban asintomáticos (50,18%). Respecto a la TSH y T4 libre la mayoría presentaron valores normales (83,77% y 94.63% respectivamente). Un pequeño porcentaje de pacientes presentó alteraciones autoinmunes en el momento del diagnóstico, ANA (15,18%) y ANCA (15,1%). El resto de los valores sólo fueron positivos en 39 pacientes (10,51%). Conclusiones Debido al bajo número de pacientes con resultado positivo de marcadores autoinmunes o demás valores analíticos elevados se puede afirmar que en la población analizada se objetiva una baja prevalencia de asociación autoinmune. Design Descriptive, observational, cross-sectional and retrospective study in the clinical records of the patients who attended the module of demyelinating diseases of the NRL Service from 7/17/79 to 5/3/19. Goals Describe the prevalence of the coexistence of multiple sclerosis and another autoimmune alteration at the time of diagnosis of multiple sclerosis. Methods We reviewed clinical histories with SAP system, we analyzed data of patients diagnosed with multiple sclerosis from 17/7/79 to 5/3/19 (577 stories). We selected those who had the immunological analytical study at the time of diagnosis (371 stories). An anonymized database was filled in with biographical data, referring to multiple sclerosis, MRI data, diagnostic confirmation of MS, lumbar puncture, analytical with immunological markers (TSH, free T4, ANA, ANCA, Autoantibody (Ac.) AntiTG, Ac. AntiTPO, Ac. Anti-ds DNA, Ac. Anti-Cardiolipin IgG, Ac. Anti-Cardiolipin IgM, Ac. Anti-β2 Glycoprotein I IgG, Ac. Anti-β2 Glycoprotein I IgM, Ac. Anti-Gliadin Peptide IgA, Ac. Anti-Gliadin Peptide IgG, Ac. Anti-tissue Transglutaminase IgA, Ac. Anti-tissue Transglutaminase IgG, Ac. Anti-Endomysium, Ac. Anti-MPO and Ac. Anti-PR3.) The extracted data were analyzed using IBM SPSS® Statistics, performing the pertinent calculations. We used descriptive as a mean and standard deviations and grouped variables with results expressed in percentages. Results There is a greater number of women in the study sample, representing a greater affectation compared to the male sex. Regarding the clinic, most of the patients were asymptomatic (50.18%). Regarding TSH and free T4, the majority presented normal values (83.77% and 94.63% respectively). A small percentage of patients presented autoimmune alterations at the time of diagnosis, ANA (15.18%) and ANCA (15.1%). The rest of the values were positive only in 39 patients 10,51%). Conclusions Due to the low number of patients with positive results of autoimmune markers or other high analytical values, it can be affirmed that a low prevalence of autoimmune association is observed in the analyzed population

Dentro de las enfermedades de etiopatogenia autoinmune, la esclerosis múltiple (EM) es una enfermedad neurodegenerativa que cursa no solo con síntomas físicos, sino también con alteraciones psicopatológicas que pueden suponer una importante carga emocional para los pacientes. Es por ello que este estudio plantea como objetivo identificar patrones de personalidad característicos entre pacientes afectos de esclerosis múltiple y su relación con la presencia de síntomas de ansiedad y/o depresión, estrategias de afrontamiento, locus de control y calidad de vida. Para ello se llevará a cabo un estudio transversal en el que se recogerán los datos de una muestra de 45 pacientes, cada uno de ellos evaluado en una sola visita. Se registrarán datos relevantes de la historia clínica y se entregará como variable principal el cuestionario NEO-FFI, así como otros cuestionarios sobre síntomas depresivos, ansiedad, calidad de vida, afrontamiento de la enfermedad y locus de control. Los datos obtenidos se analizarán con métodos de estadística descriptiva. Within autoimmune pathogenesis diseases, multiple sclerosis (MS) is a neurodegenerative disease that is not only asociated with physical symptoms, but also with psychopathological alterations that can be an important emotional burden for patients. This is why this study aims to identify characteristic personality patterns among patients affected by multiple sclerosis and their relationship with the presence of anxiety and/or depression symptoms, coping strategies, locus of control and quality of life. For this, a cross-sectional study will be carried out in which the data of a sample of 45 patients will be collected, each of them evaluated in a single visit. Relevant data from the clinical history will be recorded and the NEO-FFI questionnaire will be delivered as the main variable, as well as other questionnaires about depressive symptoms, anxiety, quality of life, disease coping and locus of control. The obtained data will be analyzed with descriptive statistics methods.